Ras Al Khaimah: A new antibiotic has been launched for treating chest infections in adult patients, it has been announced.
The antibiotic Voxin (Levofloxacin) was launched by Julphar Gulf Pharmaceutical Industries during an event on November 25.
Dr Hosam Badr, director of marketing at Julphar, said Voxin is a fluoroquinolone antibiotic that is indicated for the treatment of lower respiratory tract infections and sinusitis in adult patients.
“The antibiotic’s efficacy in treating respiratory tract infections is well documented in bioequivalence studies. Moreover, Voxin is very convenient for patients because of its simple once daily dose.”
Around 120 doctors and pharmacists attended the event to hear Dr Bassam Mahboub, president of the Emirates Allergy and Respiratory Society (EARS), and Tobias Welte, head of the Pulmonary Department and Infectious Diseases at Hannover Medical School, Germany, discuss the principles of management of chest infections and give an overview of Levofloxacin as one of the solutions for the management of such infections.
Welte showed updated clinical trials and patient cases that ensured the benefits of Levoflixacin use in respiratory tract infections, even in severe cases with resistant types of bacteria and how those patients got better in a shorter course of time.
